CoronaryAtlas logo
CoronaryAtlas
Myeloperoxidase
Pathway / Plaque inflammation

Myeloperoxidase

MPOprotein

Myeloperoxidase oxidizes LDL and generates reactive oxygen species in atherosclerotic plaques, promoting inflammation and endothelial dysfunction; also a marker of neutrophil extracellular trap formation and thrombotic activation in acute MI.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationalePMN-derived oxidative enzyme driving LDL oxidation, plaque inflammation, and NET-mediated thrombosis.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000005381

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
63
A — assay feasibility
72
E — evidence strength
12
T1DI (composite)
2
Specificity differential (R−C)-48
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 9/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 19 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma (EDTA)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Sandwich immunoassay / ELISA
Reagent / substrate
Anti-MPO antibody pair
Platform
ELISA/automated
Turnaround · availability
Send-out · CE/research

Human genetic evidence

0.004
Open Targets association (NSTEMI)

Literature evidence(40)

Clinical trials(1)